Hyblate Medical

Hyblate Medical is developing a self-adjusting ablation catheter for superior treatment of atrial fibrillation.

Product:
Hyblate increases the efficacy of ablation procedures with a proprietary catheter that self-adjusts to the particular anatomy of each patient’s pulmonary veins. Hyblate’s new generation ablation catheter is comprised of 12 independent arms, each fitted with an electrode that carries out the ablation procedure. This allows the catheter to self-adjust to each patient’s unique pulmonary vein anatomy. The design enables easier maneuverability and better contact with the targeted tissue resulting in a faster procedure and a more complete line of ablation.

Additionally, the Hyblate catheter includes a distal tip with a single electrode that can deliver point-by-point focal ablation if required by the physician during the procedure.

Hyblate’s unique AFib catheter provides:

More effective ablation (improved contact with tissue)
Improved lesion creation (continuous ablation)
Reduced tissue damage (controlled ablation)

Hyblate’s catheter is designed to work with both RF, the most common ablation energy, and electroporation, an alternative electrical energy source currently being studied in the clinical setting.

Hyblate’s treatment is expected to lead to higher success rates, reduced repeat ablation procedures, and improved patient outcomes in this very large global market.

Achievements:
Pre-clinical POC
Successful ex-vivo and in-vivo animal (pig) study with RF and lectroporation
Filed 2 patents

Team:
Rami Shachar | CEO
Prof. Mahmoud Suleiman | Co-Founder & CMO
Prof. Lior Gepstein | Co-Founder & Clinical Adviser
Robert Bash | Business Advisor

Company’s Keywords: